Expression of E cadherin and Ki 67: Emerging Prognostic Markers in Triple-Negative Breast Cancer

  • Jayaprakash Shetty
  • Chandrika RaoEmail author
Original Article


Triple-negative breast cancer (TNBC) is an aggressive subgroup of breast cancer which lacks effective target therapy. Expression of biomarkers is one of the important deciding factors for treatment strategies. The aim of this study was to evaluate expression of E cadherin and Ki 67 in relation to clinicopathological features. This prospective observational study included 141 cases of TNBC. Immunohistochemical staining was employed to analyze two biomarkers: E cadherin and Ki 67 on formalin-fixed paraffin-embedded tumor samples obtained from patients defined as TNBC. The age of the patients ranged from 26 to 84 years. Positive lymph nodes were found in 82 (58.1%). The tumor was grade 3 in 105 (74.4%). The E cadherin receptor was positive in 83 (58.8%). The Ki Index was > 10% in 89 (63.12%). The Ki 67 expression was significantly associated with a high nuclear grade (p = 0.000). The significant association noted between loss of E cadherin expression and positive lymph node (p = 0.0296). According to the results, TNBCs are frequently associated with the younger age groups, and the majority is poorly differentiated. The majorities of these have high expression of the Ki 67 and significantly associated with the higher nuclear grade. Loss of E cadherin was significantly associated with positive lymph nodes. Hence, evaluating the expression of E cadherin and Ki 67 routinely would be helpful for evaluating prognostic implications.


E cadherin Ki 67 Triple-negative breast cancer Prognostic markers 



This study was funded by the Vision group on science and technology (VGST), Government of Karnataka (GRD No. 271).


  1. 1.
    Nair N, Shet T, Parma V, Havaldar R, Gupta S, Budrukkar A et al (2018) Breast cancer in a tertiary cancer centre in India – an audit, with outcome analysis. Indian J Cancer 55:16–22CrossRefPubMedGoogle Scholar
  2. 2.
    National cancer registry program, Three year report of the PBCRs (2009–2011). Comparison of cancer incidence and patterns of all population based cancer registry. Published by NCDIR-NCRP (ICMR). Bangalore 562110. Available from: http// 2 leading sites of cancer, pg12–80. [Last accessed on 2017 Aug]
  3. 3.
    Nakagawa M, Bando Y, Nagao N, Morimoto M, Takai C, Ohnishi T et al (2011) Expression of p 53, Ki-67, E- cadherin, N- cadherin and TOP2A in triple-negative breast cancer. Anti Cancer Res 31:2389–2394Google Scholar
  4. 4.
    Ricciardi GR, Adamo B, Leni A, Licata L, Cardia R, Ferraro G et al. (2015) Androgen receptor (AR), E cadherin and Ki – 67 as emerging targets and novel prognostic markers in triple negative breast cancer (TNBC) patients. PLoS One 10(7):e0132647.
  5. 5.
    Keam B, Im SA, Lee KH, Han SW, Oh DY, Kim JH et al. (2011) Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosis. Breast Cancer Res 13R22Google Scholar
  6. 6.
    Peng Y, Butt YM, Chen B, Zang X (2017) Update on immunohistochemical analysis in breast lesions. Arch Pathol Lab Med 141:1033–1050CrossRefPubMedGoogle Scholar
  7. 7.
    Tang D, Xu S, Zang Q, Zhao W (2012) The expression and clinical significance of the androgen receptor and E cadherin in triple negative breast cancer. Med Oncol 29:526–533CrossRefPubMedGoogle Scholar
  8. 8.
    Kayahan M, Idiz UO, Gucin Z, Erozgen F, Memmi N, Muslumanoglu M et al (2014) Clinical significance of androgen receptor, CK-5/6, Ki-67 and molecular subtypes in breast cancer. J Breast Health 10:201–208CrossRefPubMedGoogle Scholar
  9. 9.
    Pan Y, Yuan Y, Liu G, Wei Y P 53 and Ki -67 as prognostic markers in triple negative breast cancer patients. PLoS One 12(2):e0172324.
  10. 10.
    Dowsett M, Neilson TO, A’Hem R, Bartlett J, Coombes RC, Cuzick J et al (2011) Assessment of Ki-67 in breast cancer: recommendations from the international Ki-67 in breast cancer working group. J Natl Cancer Inst 103:1656–1664CrossRefPubMedGoogle Scholar

Copyright information

© Indian Association of Surgical Oncology 2019

Authors and Affiliations

  1. 1.Department of PathologyK S Hegde Medical AcademyMangaloreIndia

Personalised recommendations